274 related articles for article (PubMed ID: 34397689)
1. Changes in lipidomic profile by anti-retroviral treatment regimen: An ACTG 5257 ancillary study.
Chaudhary NS; Kind T; Willig AL; Saag MS; Shrestha S; Funderburg N; Wiener HW; Overton ET; Irvin MR
Medicine (Baltimore); 2021 Jul; 100(30):e26588. PubMed ID: 34397689
[TBL] [Abstract][Full Text] [Related]
2. Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
Brown TT; Moser C; Currier JS; Ribaudo HJ; Rothenberg J; Kelesidis T; Yang O; Dubé MP; Murphy RL; Stein JH; McComsey GA
J Infect Dis; 2015 Oct; 212(8):1241-9. PubMed ID: 25948863
[TBL] [Abstract][Full Text] [Related]
3. Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.
Kelesidis T; Tran TT; Stein JH; Brown TT; Moser C; Ribaudo HJ; Dube MP; Murphy R; Yang OO; Currier JS; McComsey GA
Clin Infect Dis; 2015 Aug; 61(4):651-60. PubMed ID: 25904376
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial).
Slama L; Landman R; Assoumou L; Benalycherif A; Samri A; Joly V; Pialoux G; Valin N; Cabié A; Duvivier C; Lambert-Niclot S; Marcelin AG; Peytavin G; Costagliola D; Girard PM;
J Antimicrob Chemother; 2016 Aug; 71(8):2252-61. PubMed ID: 27068399
[TBL] [Abstract][Full Text] [Related]
5. Short-term cost analysis of raltegravir versus atazanavir + ritonavir or darunavir + ritonavir for treatment-naive adults with HIV-1 infection in the United States.
Brogan AJ; Davis AE; Goodwin B
PLoS One; 2018; 13(8):e0203293. PubMed ID: 30161205
[TBL] [Abstract][Full Text] [Related]
6. Distinct Lipidomic Signatures in People Living With HIV: Combined Analysis of ACTG 5260s and MACS/WIHS.
Jao J; Balmert LC; Sun S; McComsey GA; Brown TT; Tien PC; Currier JS; Stein JH; Qiu Y; LeRoith D; Kurland IJ
J Clin Endocrinol Metab; 2022 Jan; 107(1):119-135. PubMed ID: 34498048
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257.
Ofotokun I; Na LH; Landovitz RJ; Ribaudo HJ; McComsey GA; Godfrey C; Aweeka F; Cohn SE; Sagar M; Kuritzkes DR; Brown TT; Patterson KB; Para MF; Leavitt RY; Villasis-Keever A; Baugh BP; Lennox JL; Currier JS;
Clin Infect Dis; 2015 Jun; 60(12):1842-51. PubMed ID: 25767256
[TBL] [Abstract][Full Text] [Related]
8. A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results.
Kozal MJ; Lupo S; DeJesus E; Molina JM; McDonald C; Raffi F; Benetucci J; Mancini M; Yang R; Wirtz V; Percival L; Zhang J; Zhu L; Arikan D; Farajallah A; Nguyen BY; Leavitt R; McGrath D; Lataillade M; The Spartan Study Team
HIV Clin Trials; 2012; 13(3):119-30. PubMed ID: 22592092
[TBL] [Abstract][Full Text] [Related]
9. Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study.
Squires K; Kityo C; Hodder S; Johnson M; Voronin E; Hagins D; Avihingsanon A; Koenig E; Jiang S; White K; Cheng A; Szwarcberg J; Cao H
Lancet HIV; 2016 Sep; 3(9):e410-e420. PubMed ID: 27562742
[TBL] [Abstract][Full Text] [Related]
10. Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study.
Jao J; Yu W; Patel K; Miller TL; Karalius B; Geffner ME; DiMeglio LA; Mirza A; Chen JS; Silio M; McFarland EJ; Van Dyke RB; Jacobson D;
HIV Med; 2018 Mar; 19(3):175-183. PubMed ID: 29159965
[TBL] [Abstract][Full Text] [Related]
11. Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trial.
Avihingsanon A; Hughes MD; Salata R; Godfrey C; McCarthy C; Mugyenyi P; Hogg E; Gross R; Cardoso SW; Bukuru A; Makanga M; Badal-Aesen S; Mave V; Ndege BW; Fontain SN; Samaneka W; Secours R; Van Schalkwyk M; Mngqibisa R; Mohapi L; Valencia J; Sugandhavesa P; Montalban E; Munyanga C; Chagomerana M; Santos BR; Kumarasamy N; Kanyama C; Schooley RT; Mellors JW; Wallis CL; Collier AC; Grinsztejn B;
J Int AIDS Soc; 2022 Jun; 25(6):e25905. PubMed ID: 36039892
[TBL] [Abstract][Full Text] [Related]
12. Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s.
Kelesidis T; Tran TTT; Brown TT; Moser C; Ribaudo HJ; Dube MP; Yang OO; McComsey GA; Stein JH; Currier JS
Antivir Ther; 2017; 22(2):113-126. PubMed ID: 27661466
[TBL] [Abstract][Full Text] [Related]
13. Body Composition Changes After Initiation of Raltegravir or Protease Inhibitors: ACTG A5260s.
McComsey GA; Moser C; Currier J; Ribaudo HJ; Paczuski P; Dubé MP; Kelesidis T; Rothenberg J; Stein JH; Brown TT
Clin Infect Dis; 2016 Apr; 62(7):853-62. PubMed ID: 26797215
[TBL] [Abstract][Full Text] [Related]
14. Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 Trial.
Ammassari A; Stöhr W; Antinori A; Molina JM; Schwimmer C; Domingo P; Thalme A; Di Pietro M; Wallet C; Pozniak A; Richert L; Raffi F;
J Acquir Immune Defic Syndr; 2018 Dec; 79(4):481-490. PubMed ID: 30365452
[TBL] [Abstract][Full Text] [Related]
15. Blood Telomere Length Changes After Ritonavir-Boosted Darunavir Combined With Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected With HIV-1.
Stella-Ascariz N; Montejano R; Rodriguez-Centeno J; Alejos B; Schwimmer C; Bernardino JI; Rodes B; Allavena C; Hoffmann C; Gisslén M; de Miguel R; Esteban-Cantos A; Wallet C; Raffi F; Arribas JR;
J Infect Dis; 2018 Oct; 218(10):1523-1530. PubMed ID: 29982509
[TBL] [Abstract][Full Text] [Related]
16. Effects of atazanavir, darunavir, and raltegravir on fat and muscle among persons living with HIV.
Adrian S; Miao H; Feng H; Scherzinger A; Nardini G; Beghetto B; Roncaglia E; Ligabue G; Milic J; Guaraldi G; Lake JE; Erlandson KM
HIV Res Clin Pract; 2020 Aug; 21(4):91-98. PubMed ID: 32878571
[TBL] [Abstract][Full Text] [Related]
17. Determinants of blood telomere length in antiretroviral treatment-naïve HIV-positive participants enrolled in the NEAT 001/ANRS 143 clinical trial.
Alejos B; Stella-Ascariz N; Montejano R; Rodriguez-Centeno J; Schwimmer C; Bernardino JI; Rodes B; Esser S; Goujard C; Sarmento-Castro R; De Miguel R; Esteban-Cantos A; Wallet C; Raffi F; Arribas JR;
HIV Med; 2019 Nov; 20(10):691-698. PubMed ID: 31532902
[TBL] [Abstract][Full Text] [Related]
18. Brief Report: Switch to Ritonavir-Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot Study.
van Lunzen J; Pozniak A; Gatell JM; Antinori A; Klauck I; Serrano O; Baakili A; Osiyemi O; Sevinsky H; Girard PM
J Acquir Immune Defic Syndr; 2016 Apr; 71(5):538-43. PubMed ID: 26605505
[TBL] [Abstract][Full Text] [Related]
19. Bone Mineral Density and Vitamin D Levels in HIV Treatment-Naïve African American Individuals Randomized to Receive HIV Drug Regimens.
Cook PP; Stang AT; Walker LR; Akula SM; Cook FJ
South Med J; 2016 Nov; 109(11):712-717. PubMed ID: 27812717
[TBL] [Abstract][Full Text] [Related]
20. Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study.
Latini A; Fabbiani M; Borghi V; Sterrantino G; Giannetti A; Lorenzini P; Loiacono L; Ammassari A; Bellagamba R; Colafigli M; D'Ettorre G; Di Giambenedetto S; Antinori A; Zaccarelli M
BMC Infect Dis; 2016 Aug; 16(1):401. PubMed ID: 27515949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
